Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Quarterly results
Acq. announced
CC transcript
Embarq CORP (EQ) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/21/2020 GN Equillium to Present at Jefferies Virtual Healthcare Conference
05/13/2020 GN Equillium Reports First Quarter 2020 Financial Results
05/07/2020 GN Equillium to Present at 2020 RBC Capital Markets Virtual Global Healthcare Conference
03/30/2020 GN Equillium Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital
03/26/2020 GN Equillium Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update
02/13/2020 GN Equillium to Present at 9th Annual SVB Leerink Global Healthcare Conference
01/29/2020 GN Equillium to Present Translational Preclinical Data Demonstrating Increased Survival and Decreased Disease Severity in Models of Graft-Versus-Host Disease Treated with Itolizumab at the Transplantation & Cellular Therapy Meetings of ASTCT & CIBMTR
12/12/2019 GN Equillium & Biocon Expand Exclusive Licensing Agreement for Itolizumab to Include Australia and New Zealand
12/09/2019 GN Equillium Granted U.S. FDA Fast Track Designation for Itolizumab for the Treatment of Lupus Nephritis
11/26/2019 GN Equillium to Present Translational Data on Itolizumab for Acute Graft-Versus-Host Disease at 61st American Society of Hematology (ASH) Annual Meeting and Exposition
11/15/2019 GN Equillium Featured in Panel Discussion at Capital Markets Day for Kidney Health
11/12/2019 GN Equillium Announces Leadership Updates
11/12/2019 GN Equillium Reports Third Quarter 2019 Financial Results and Recent Highlights
11/06/2019 GN Equillium to Present New Data and Insights on the CD6-ALCAM Pathway in Lupus Nephritis at ACR 2019
10/31/2019 GN Orgenesis Appoints Bala S. Manian to its Scientific Advisory Board
10/01/2019 GN Equillium Announces Initiation of the EQUALISE Phase 1b Clinical Trial of Itolizumab for Patients with Lupus Nephritis and Provides Business Update
09/17/2019 GN Equillium to Host Business Update Call on October 1, 2019
08/27/2019 GN Equillium to Present at H. C. Wainwright 21st Annual Global Investment Conference
08/12/2019 GN Equillium Reports Second Quarter 2019 Financial Results and Recent Highlights
05/23/2019 GN Equillium to Present at Jefferies 2019 Healthcare Conference
05/13/2019 GN Equillium Reports First Quarter 2019 Financial Results and Recent Highlights
05/06/2019 GN Equillium Expands Scientific and Clinical Advisory Team
04/16/2019 GN Equillium to Present at Solebury Trout Class of 2018 Biotech IPO Investor Day
03/28/2019 GN Equillium to Present at H.C. Wainwright Global Life Sciences Conference
03/27/2019 GN Equillium Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights
02/26/2019 GN Equillium Announces Plan to Develop EQ001 for the Treatment of Lupus Nephritis
02/21/2019 GN Equillium to Present at Leerink Partners Global Healthcare Conference
02/19/2019 GN Equillium to Host Business Update Call on February 26
02/07/2019 GN Equillium Granted U.S. FDA Orphan Drug Designations for EQ001 (itolizumab) for both the Prevention and Treatment of Acute Graft-Versus-Host Disease
12/19/2018 GN Equillium Granted U.S. FDA Fast Track Designation for EQ001 for the Treatment of Acute Graft-Versus-Host Disease
11/15/2018 GN Equillium Reports Third Quarter 2018 Financial Results and Recent Highlights
10/12/2018 GN Equillium Announces Pricing of Initial Public Offering
08/07/2009 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
07/13/2009 15-15D Form 15-15D -- Suspension of duty to report [Section 13 and 15(d)]
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy